News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genetic Technologies Limited (GTG.AX) Executes Agreement With Promega Corporation


3/24/2014 11:09:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MELBOURNE, AUSTRALIA--(Marketwired - March 24, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) announced today that in compliance with the ASX Continuous Disclosure Rules, the company is pleased to report the execution of a Settlement, Covenant and License Agreement with Promega Corporation, which has a principal place of business in Madison, Wisconsin, USA.

Under this Agreement, GTG grants broad rights to Promega in relation to GTG's Intron Sequence Analysis and Genomic Mapping patents. The precise commercial terms of this Agreement are covered by formal confidentiality provisions and cannot be disclosed.

About Genetic Technologies Limited
Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting. The Company has operations in Australia and the U.S. and is dual-listed on the ASX (GTG.AX) and NASDAQ (GENE). Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. Its U.S. subsidiary, Phenogen Sciences, offers novel predictive testing and assessment tools to help physicians proactively manage women's health. Phenogen's lead product, BREVAGen™, is a first in class, clinically validated risk assessment test for non-familial breast cancer. For more information, please visit http://www.gtglabs.com, http://www.phenogensciences.com.

Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.


FOR FURTHER INFORMATION PLEASE CONTACT
Dr. Mervyn Jacobson
VP, Global Licensing and Intellectual Property
Genetic Technologies Limited
Phone: +61 419 657 915



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES